FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947953896> ?p ?o ?g. }

• W2947953896 endingPage "194" @default.
• W2947953896 startingPage "189" @default.
• W2947953896 abstract "Prisoners and other high-risk patients who show a sustained virological response (SVR) after treatment for hepatitis C virus (HCV) can become reinfected. We aimed to calculate the rate of HCV reinfection in a large cohort of inmates with SVR and to determine factors that predict reinfection. We included all inmates treated for hepatitis C in Catalonia (Spain) from January 2002 to December 2016 who achieved SVR and in whom viral load was subsequently determined. The incidence rate was calculated per 100 person-years (100 py) of follow up. Risk factors associated with reinfection were evaluated by bivariate log-rank test and multivariate Cox regression. Hazard ratio (HR) and their 95% confidence intervals (CI) were calculated. 602 patients were included, with a mean age of 37.9 years: 95% were men, 74.1% had a history of intravenous drug use (IDU) and 28.7% were HIV-infected. Patients were followed for a total of 2154.9 years (average 3.58 ± 3.1 years). 63 (10.5%) had HCV reinfection. 41 (65.1%) presented different genotype/subgenotype, 8 the initial genotype/subgenotype, and in 14 (22.2%) the genotype could not be determined. Of the 21 reinfected patients who were interviewed, 20 (95.2%) reported IDU after antiviral treatment, and 7 (33.3%) during treatment. The overall incidence of reinfection was 2.9 cases per 100 py. All reinfections occurred in patients with IDU history. At multivariate level, HIV infection was associated with reinfection (HR = 3.03; CI:1.82-5.04). In HIV-infected inmates with IDU history, the rate of reinfection of HCV post-SVR is very high. Prisons play a key role in the detection and treatment of infection and reinfection by HCV and in the post-treatment monitoring in these patients, which should be combined with counseling and the optimization of the harm reduction programs. Effective control of these vulnerable groups favours the elimination of the HCV infection." @default.
• W2947953896 created "2019-06-07" @default.
• W2947953896 creator A5009210846 @default.
• W2947953896 creator A5010592399 @default.
• W2947953896 creator A5035888463 @default.
• W2947953896 creator A5035995209 @default.
• W2947953896 creator A5037887346 @default.
• W2947953896 creator A5039062565 @default.
• W2947953896 creator A5040152459 @default.
• W2947953896 creator A5042091871 @default.
• W2947953896 creator A5047224025 @default.
• W2947953896 creator A5047482028 @default.
• W2947953896 creator A5047899045 @default.
• W2947953896 creator A5058694249 @default.
• W2947953896 creator A5060319010 @default.
• W2947953896 creator A5065898013 @default.
• W2947953896 creator A5087915271 @default.
• W2947953896 date "2019-10-01" @default.
• W2947953896 modified "2023-10-18" @default.
• W2947953896 title "Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002–2016" @default.
• W2947953896 cites W1527786018 @default.
• W2947953896 cites W1595559280 @default.
• W2947953896 cites W1865766583 @default.
• W2947953896 cites W1964273353 @default.
• W2947953896 cites W2006747389 @default.
• W2947953896 cites W2021635172 @default.
• W2947953896 cites W2025378444 @default.
• W2947953896 cites W2037595198 @default.
• W2947953896 cites W2081569952 @default.
• W2947953896 cites W2087509554 @default.
• W2947953896 cites W2092864701 @default.
• W2947953896 cites W2094997729 @default.
• W2947953896 cites W2106400283 @default.
• W2947953896 cites W2132682504 @default.
• W2947953896 cites W2146571916 @default.
• W2947953896 cites W2155380461 @default.
• W2947953896 cites W2169986198 @default.
• W2947953896 cites W2201944704 @default.
• W2947953896 cites W2254380230 @default.
• W2947953896 cites W2258490349 @default.
• W2947953896 cites W2274680380 @default.
• W2947953896 cites W2463563063 @default.
• W2947953896 cites W2529503072 @default.
• W2947953896 cites W2562778217 @default.
• W2947953896 cites W2566331999 @default.
• W2947953896 cites W2626049294 @default.
• W2947953896 cites W2750028296 @default.
• W2947953896 cites W2804812145 @default.
• W2947953896 cites W2807308548 @default.
• W2947953896 doi "https://doi.org/10.1016/j.drugpo.2019.05.014" @default.
• W2947953896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31160156" @default.
• W2947953896 hasPublicationYear "2019" @default.
• W2947953896 type Work @default.
• W2947953896 sameAs 2947953896 @default.
• W2947953896 citedByCount "14" @default.
• W2947953896 countsByYear W29479538962019 @default.
• W2947953896 countsByYear W29479538962020 @default.
• W2947953896 countsByYear W29479538962021 @default.
• W2947953896 countsByYear W29479538962022 @default.
• W2947953896 countsByYear W29479538962023 @default.
• W2947953896 crossrefType "journal-article" @default.
• W2947953896 hasAuthorship W2947953896A5009210846 @default.
• W2947953896 hasAuthorship W2947953896A5010592399 @default.
• W2947953896 hasAuthorship W2947953896A5035888463 @default.
• W2947953896 hasAuthorship W2947953896A5035995209 @default.
• W2947953896 hasAuthorship W2947953896A5037887346 @default.
• W2947953896 hasAuthorship W2947953896A5039062565 @default.
• W2947953896 hasAuthorship W2947953896A5040152459 @default.
• W2947953896 hasAuthorship W2947953896A5042091871 @default.
• W2947953896 hasAuthorship W2947953896A5047224025 @default.
• W2947953896 hasAuthorship W2947953896A5047482028 @default.
• W2947953896 hasAuthorship W2947953896A5047899045 @default.
• W2947953896 hasAuthorship W2947953896A5058694249 @default.
• W2947953896 hasAuthorship W2947953896A5060319010 @default.
• W2947953896 hasAuthorship W2947953896A5065898013 @default.
• W2947953896 hasAuthorship W2947953896A5087915271 @default.
• W2947953896 hasConcept C120665830 @default.
• W2947953896 hasConcept C121332964 @default.
• W2947953896 hasConcept C126322002 @default.
• W2947953896 hasConcept C142462285 @default.
• W2947953896 hasConcept C144024400 @default.
• W2947953896 hasConcept C149923435 @default.
• W2947953896 hasConcept C203014093 @default.
• W2947953896 hasConcept C207103383 @default.
• W2947953896 hasConcept C2776455275 @default.
• W2947953896 hasConcept C3013748606 @default.
• W2947953896 hasConcept C44249647 @default.
• W2947953896 hasConcept C50382708 @default.
• W2947953896 hasConcept C61511704 @default.
• W2947953896 hasConcept C71924100 @default.
• W2947953896 hasConcept C72563966 @default.
• W2947953896 hasConceptScore W2947953896C120665830 @default.
• W2947953896 hasConceptScore W2947953896C121332964 @default.
• W2947953896 hasConceptScore W2947953896C126322002 @default.
• W2947953896 hasConceptScore W2947953896C142462285 @default.
• W2947953896 hasConceptScore W2947953896C144024400 @default.
• W2947953896 hasConceptScore W2947953896C149923435 @default.
• W2947953896 hasConceptScore W2947953896C203014093 @default.

• next